Trial Profile
A Pilot Investigation of the Nasal Mucosal Absorption, Retention, and Metabolism of Ciclesonide When Administered as a Hypotonic Versus an Isotonic Formulation of Ciclesonide Nasal Spray When Each Formulation Is Administered to Currently Symptomatic Patients (18 Years or Older) With Documented Perennial Allergic Rhinitis (PAR).
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase IV
Latest Information Update: 11 Aug 2023
Price :
$35
*
At a glance
- Drugs Ciclesonide (Primary)
- Indications Perennial allergic rhinitis
- Focus Pharmacokinetics
- 19 Jul 2010 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 29 Nov 2008 New trial record.